Hemas Pharmaceuticals launches diabetes screening and awareness with Medihelp Hospitals

From left: Dr. Mahesha Ranasoma and Nishantha Jayamanne exchange the partnership agreement marking their collaboration

Hemas Pharmaceuticals (Pvt) Ltd recently partnered with Medihelp Hospitals and conducted Suwajeewa Diabetes Screening and Awareness Programmes. 

The first of its kind, the initial programme was held at the Medihelp Wellness Centre in Colombo 02 on the 23rd of October, followed by the second on the 28th at Medihelp Hospital Bandaragama, and the third on the 30th at Medihelp Homagama Hospital.

Aimed at offering a helping hand to patients diagnosed with diabetes, the programme made a range of health services available to those in attendance. In addition to screening and early diabetes detection, patients were offered blood sugar testing, blood pressure measurement, BMI evaluation, and screenings for glaucoma and retinopathy, free of charge. The event also offered patients and attendees comprehensive, holistic care, with options across the fields of integrated medical, nutritional, and lifestyle support. 

Discussing the event, Dr. Mahesha Ranasoma, Managing Director of Hemas Pharmaceuticals, said, “As Sri Lanka’smarket leader in pharmaceutical distribution, we recognise our responsibility in furthering efforts to support and care for patients living diabetes. Through the Suwajeewa Diabetes Screening and Awareness Programmes, we’re expanding our ability to offer a range of services that will not only ease the lives of patients but also form the foundation for large scale initiatives in the future.” 

Working in collaboration with Medihelp Hospitals, the event highlighted and aligned with Hemas Pharmaceutical’s mission to empower people to live well. Understanding the right of every citizen to physical health and wellbeing, the initiative provided fundamental support directed at improving the lives of those living with diabetes. 

Nishantha Jayamanne, COO of Medihelp Hospitals, added “We are particularly focused on promoting the practice of screening for non-communicable diseases (NCDs) to enable early detection and treatment. Together, with our shared goals, we look forward to enhancing the universal right to effective and accessible healthcare.”

Thescreening programmesfurther provided attendees a chance to equip themselves with the knowledge and education needed to manage diabetes independently. In addition to encouraging effective and consistent care, it set a foundation for building awareness of diabetes and its related complications. The initiative represents the newest chapter in Hemas Pharmaceuticals’ mission to elevate the healthcare system by improving accessibility to healthcare services and information.